Qiagen, Inc.

United States

Qiagen, Inc.

United States
SEARCH FILTERS
Time filter
Source Type

Dublin, May 05, 2017 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Global In-Vitro Diagnostics (IVD) Market: Analysis and Forecast 2017-2023 (Focus on Product Type, Test Type, Application, and Competitive Landscape)" report to their offering. IVD is expected to increase to $76 billion by 2023 and increase its influence over healthcare spending globally. The category's rate of growth is accelerating due to a number of key macro forces, such as demand from emerging economies, aging population, evolving clinician attitudes, and a much needed push towards theranostics and personalized medicine. The molecular diagnostics (MDx) segment has continually outperformed the broader IVD category, and is a key driver of this market's growth. The In-Vitro Diagnostic (IVD) sector is playing a central role in the shifting the healthcare and drug discovery landscape. Invigorated by the demand for changes in the healthcare environment and driven by a wave of molecular advances, the in-vitro diagnostic sector is actively engaged in innovation of new tools and technologies. Present day healthcare systems are already strained under the burden of a rising demand and soaring costs; and this trend is projected to exacerbate in coming years. The current challenges tend to be chronic age-related conditions such as cardiovascular diseases, cancer, and neurological diseases, and these will grow more prevalent as population demographics shift upwards. The report includes the company profiles for leading players in the IVD market which enables the readers understand the current competitive scenario that prevails in this industry. Some of the key player include Thermo Fisher, Roche, Abbott, Siemens Healthineers, Becton, Dickinson, Johnson & Johnson, Qiagen, and Danaher Corporation. Key Topics Covered: Executive Summary 1 Research Scope and Methodology 1.1 Scope of the Report 1.2 Global IVD Market Research Methodology 2 Market Overview 3 Market Dynamics 4 IVD Market Demand and Supply Analysis 5 Competitive Insights 6 Global IVD Market by Product Type, 2016-2023 7 Global IVD Market by Test Type, 2016-2023 8 Global IVD Market by Application Type, 2016-2023 9 Global IVD Market by End User Type, 2016-2023 10 Global IVD Market by Geography, 2016-2023 11 End User Perception About IVD 12 Market Analytics & Recommendations 13 Competitive Landscape 14 Company Profile For more information about this report visit http://www.researchandmarkets.com/research/l9488n/global_invitro


Methods and materials for improving nucleic acid or protein recovery from samples preserved in liquid cytological preservative solutions by utilizing scavenging agents, such as hydrazine- and hydrazide-containing compounds, are provided. Lysis solutions comprising hydrazine- and hydrazide-containing compounds and kits comprising the same are also provided.


Target-specific hybrid capture (TSHC) provides a nucleic acid detection method that is not only rapid and sensitive, but is also highly specific and capable of discriminating highly homologous nucleic acid target sequences. The method produces DNA:RNA hybrids which can be detected by a variety of methods.


Patent
Qiagen, Inc. | Date: 2012-04-12

The invention relates to a simple, reproducible, fast, and accurate method of quantifying and measuring telomeres in a clinical sample. The invention further relates to kits comprising premixed and optimized buffers, DNA polymerase, primers, and instructions for the detection of telomere length and quantities. Also envisioned are complete kits further including instrumentalities for the detection of telomere length and quantities.


Patent
Qiagen, Inc. | Date: 2012-09-14

The present invention comprises a method that provides fast and reliable results for detecting the presence of a target nucleic acid molecule in a sample.


Methods are provided for genotyping a target nucleic acid in a sample. In various aspects, the methods comprise generating nucleic acid hybrids between probes specific for the genotypes of interest and the target nucleic acid and detecting hybridization in the sample. In other aspects, the methods comprise using multi-probe mixtures to reduce the volume of sample necessary to determine the genotype of the target nucleic acid.


Methods and materials for determining the presence of at least one nucleic acid in a sample are provided, said methods comprising (1) a purification step using sequence specific hybrid capture; (2) an amplification step; and (3) a detection step using two separate sequence-specific polynucleotide probes. Also provided are nucleic acids comprising SEQ ID NO: 1 to SEQ ID NO: 727 and nucleic acid probes and probe sets comprising the same.


A method for isothermal amplification of a target nucleic acid sequence is disclosed. The target nucleic acid is amplified by an enzyme with helicase activity and an enzyme with reverse transcriptase activity and DNA-dependant DNA polymerase activity. Also disclosed is a kit for isothermal amplification of a target nucleic acid sequence, including HPV nucleic acids. The kit comprises a first enzyme with helicase activity and a second enzyme having both reverse transcriptase activity and DNA-dependant DNA polymerase activity.


Patent
Qiagen, Inc. | Date: 2011-01-07

A water treatment apparatus with a first filtration system and a second filtration system is disclosed. The first filtration system provides purified water to an automated assay device. The second filtration system receives wastewater from an outlet and removes contaminants from the wastewater which allows for direct disposal of the wastewater via environmentally responsible means. An automated assay device comprising the water treatment apparatus and a method of treating water used by the automated assay device is also disclosed.


Patent
Qiagen, Inc. | Date: 2012-02-23

Provided are nucleic acids capable of hybridizing to HPV 16 and/or HPV 18 nucleic acids, in particular, mRNA encoding E2 and E6-7 gene products. Such nucleic acids are useful in methods of isolating RNA from a biological sample, methods and means for determining the presence of particular RNA splice-form variants in a biological sample, methods and means for determining the relative ratio of RNA ratios in a biological sample, methods and means for predicting the progression of precancerous cervical lesions, and methods and means for detecting disruption of genes or gene expression.

Loading Qiagen, Inc. collaborators
Loading Qiagen, Inc. collaborators